Valproic acid as adjuvant treatment for convulsive status epilepticus: a randomised clinical trial

Abstract

Background Generalised convulsive status epilepticus (GCSE) is a medical emergency. Guidelines recommend a stepwise strategy of benzodiazepines followed by a second-line anti-seizure medicine (ASM). However, GCSE is uncontrolled in 20–40% patients and is associated with protracted hospitalisation, disability, and mortality. The objective was to determine whether valproic acid (VPA) as complementary treatment to the stepwise strategy improves the outcomes of patients with de novo established GCSE. Methods This was a multicentre, double-blind, randomised controlled trial in 244 adults admitted to intensive care units for GCSE in 16 French hospitals between 2013 and 2018. Patients received standard care of benzodiazepine and a second-line ASM (except VPA). Intervention patients received a 30 mg/kg VPA loading dose, then a 1 mg/kg/h 12 h infusion, whilst the placebo group received an identical intravenous administration of 0.9% saline as a bolus and continuous infusion. Primary outcome was proportion of patients discharged from hospital by day 15. The secondary outcomes were seizure control, adverse events, and cognition at day 90. Results A total of 126 (52%) and 118 (48%) patients were included in the VPA and placebo groups. 224 (93%) and 227 (93%) received a first-line and a second-line ASM before VPA or placebo infusion. There was no between-group difference for patients hospital-discharged at day 15 [VPA, 77 (61%) versus placebo, 72 (61%), adjusted relative risk 1.04; 95% confidence interval (0.89–1.19); p = 0.58]. There were no between-group differences for secondary outcomes. Conclusions VPA added to the recommended strategy for adult GCSE is well tolerated but did not increase the proportion of patients hospital-discharged by day 15. Trial registration No. NCT01791868 (ClinicalTrials.gov registry), registered: 15 February 2012.

Customized Proteinaceous Nanoformulation for In Vivo Chemical Reprogramming

“…For instance, the therapeutic dose of VPA was 14.42 mg kg −1 , which is significantly lower than the doses typically used in clinical trials (30 mg kg −1 for psychiatric diseases treatment). [36,37] Similarly, the cyclic pifthrin-𝛼 was transiently administered at a safe therapeutic dose of 1 μm to enhance cell proliferation. [38][39][40][41][42] Studies have confirmed that this treatment does not disrupt the tumor suppressor function of p53 signalling, [43] thus eliminating any potential oncogenic risk.…”

“…Directly administering M7‐PNF into the dermis through local injection has been shown to enhance the efficacy and safety of the drug compared to intravenous administration. [ 36 ] Future research may explore the application of M7‐PNF through microneedling, dressing or creating a medical patch to enhance its clinical utility with improved efficiency and convenience in administration. Overall, our proteinaceous nanoformulation platform offers an advanced approach for in situ generation of native SwGs without the need for exogenous cell transplantation or gene manipulation, which has translational potential for clinical therapeutics.…”